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Abstract 
Purpose: We tried to compare the effectiveness of posterior sub-Tenon’s capsule triamcinolone 
acetonide (STTA) injection to that of pars plana vitrectomy (PPV) for diabetic macular edema 
(DME).  
Patients and methods: We investigated the clinical records of 50 patients (52 eyes) with DME. 26 
eyes underwent vitrectomy combined with cataract surgery, while the other 26 underwent STTA (20 
mg). We measured the best-corrected visual acuity (BCVA) and central macular thickness (CMT) by 
optical coherence tomography before and at 1, 3, 6 months after treatment.  
Results: There were no significant differences between STTA and PPV group in the BCVA and CMT 
before or at any time after the treatment. There were significant differences between the 
before-treatment CMT and after-treatment CMT in both STTA and PPV groups,.  
Conclusion: Our results suggest that STTA can improve DME to the same extent of PPV.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction  
Diabetic macular edema (DME) is one major cause of visual acuity decrease for diabetic patients 
suffering diabetic retinopathy (DR).¹⁾ Several treatments, such as grid laser photocoagulation, 
intravitreal injection of triamcinolone acetonide (IVTA), posterior sub-Tenon’s capsule 
triamcinolone acetonide  injection(STTA), pars plana vitrectomy (PPV), subthreshold micropulse 
diode laser photocoagulation, and intravitreal injection of anti-vascular endothelial growth factor 
(VEGF) drugs have been done for DME.²⁾⁻⁹⁾ However, which treatment is most effective is still 
controversial.¹⁾  
There are reports which compare the effectiveness of IVTA to PPV¹⁰⁾, and IVTA to STTA¹¹⁾, but we 
couldn’t find any reports comparing the effectiveness of PPV to STTA. So, we tried to compare the 
effectiveness of STTA to PPV for DME eyes. 
 
 
Patients and methods  
We investigated the clinical records of 52 eyes of 50 DME patients who were treated at Chiba 
University Hospital. Clinical data and features are shown in table1. Twenty-six eyes of 26 patients 
had undergone 20 mg of STTA alone from January 1, 2010 to December 31, 2010. Among these 
eyes, 5 eyes were pseudophakic, and 3 eyes underwent STTA twice. In contrast, 26 eyes of 24 
patients underwent vitrectomy combined with cataract surgery from January 1, 2009 to December 31, 
2010. During the surgery, vitreous and posterior vitreous membrane was removed by using 
triamcinolone acetonide for the purpose of  visualizing the vitreous. Furthermore, some operators 
combine the internal limiting membrane peeling. Five eyes had already undergone cataract surgery, 
and underwent vitrectomy only at that time. The other 21 eyes had cataracts, so they underwent the 
combination of vitrectmy and cataract surgery. The indication of vitrectomy for DME was not 
specifically determined in our hospital. We chose vitrectomy when the posterior vitreous detachment 
didn’t occur, and patients agreed to that treatment. Also, the indication of STTA for DME was not 
determined. If the patients wanted conservative treatment, we chose STTA  as one option. Previous 
study reported that there was a tendency that the patients with slightly thick fovea underwent STTA 
and vitrectimy compared with other treatments.⁸⁾  
We explained the procedures of this study to all patients, and obtained informed consent from them. 
We followed the World Medical Association Declaration of Helsinki, and obtained the approval from 
the Institutional Review Board of Chiba University Hospital for this study.  
We measured the central macular thickness (CMT) using spectral domain-optical coherence 
tomography (SD-OCT) before and 1, 3, 6 months after the treatment. We also measured the 
best-corrected visual acuity (BCVA) before and 1, 3, 6 months after the treatment. 
We expressed the data by the means ± standard deviations (SDs). We determined the significance by 
using Student’s t-tests, paired t-tests, chi-square tests, and repeated measured analysis of variance 
(ANOVA). We evaluated that P<0.05 was significant.  
 
 
Results  
Clinical data is shown in Table 1. There were no significant differences in sex, age, numbers of 
pseudophakic patients, HbA1c , before treatment BCVA, and CMT between PPV and STTA groups. 
Twenty one eyes underwent pan retinal photocoagulation (PRP) in the PPV group, and 12 eyes that 
underwent PRP in the STTA group. That made significant difference. In the STTA group, before 
treatment BCVA was 0.65±0.4 logarithm of the minimum angle of resolution (logMAR) units, and in 
the PPV group, that was 0.77±0.3 logMAR units (P=0.237; Student’s t-test). At 1, 3, and 6 months, 
the BCVA at the STTA group was 0.60±0.4, 0.59±0.5, and 0.64±0.5, and 0.68±0.4, 0.59±0.4, and 
0.59±0.4 respectively at the PPV group (Figure1, 3). There were not significant differences in the 
BCVA between the two groups before and at any time after treatment (P=0.441, P=0.960, P=0.717 
respectively by Student’s t-tests, and P=0.5477 by repeated measured ANOVA). In the STTA group, 
there were no significant differences between the before treatment BCVA and at 1, 3, 6 months after 
treatment respectively (P=0.226, P=0.340, P=0.775 respectively by paired t-tests). The BCVA in the 
PPV group, there was no significant difference between the pre-treatment and 1 month after PPV, but 
there were significant differences between the pre-treatment and 3, 6 months after PPV (P=0.389, 
P=0.0066, P=0.0169 respectively by paired t-tests). 
Before treatment, CMT was 569.2±167 μm in the STTA group and 534.4±157 μm in the PPV group.  
At 1, 3, 6months after the treatment, CMT was 356.1±116 μm, 326.7±111.7 μm, 377.4±137.6 μm, in 
the STTA group, and 386.8±175 μm, 354.2±101.7 μm, 354.2±156.4 μm in the PPV group (Figure 2, 
4). There were not significant differences of CMT between the STTA and PPV groups before and at 
any time after the PPV (P=0.444, P=0.460, P=0.469, P=0.273 respectively by Student’s t-tests and 
P=0.2053 by repeated measured ANOVA). In both STTA and PPV groups, CMT made significant 
differences between before treatment group and 1, 3, 6 months after treatment groups. (STTA; 
P<0.0001, P<0.0001, P=0.0001 respectively by paired t-tests, PPV; P=0.0013, P<0.0001, P<0.0001 
respectively by paired t-tests). 
Three eyes in the STTA group increased intraocular pressure (IOP) temporarily, and underwent eye 
drop treatment. One eye in the PPV group also increased IOP, another eye had wound infection but 
that was not endophthalmitis. 
 
 
Discussion  
IVTA was reported to significantly reducing the CMT in DME eyes, and that there was no 
significant difference in CMT between IVTA and PPV group 3 months after the treatment. ¹⁰⁾That 
report coincided with our results. Also, DME recurred 6 months after IVTA in that report¹⁰⁾, while in 
our study, 3 eyes recurred DME 3 to 6 months after STTA and retreated with STTA. PPV group 
remained resolved after treatment. ¹⁰⁾ Those results suggest that repeated treatment of IVTA or STTA 
for refractory DME is considerable 3 to 6 months after first treatment.  
IVTA is reportedly more effective than STTA for DME within 3 months, but the benefit is not 
distinct after that period.¹¹⁾So, our results suggest that although DME sometimes recurs, STTA is 
effective to the same extent of IVTA and PPV during the short period.  
When we performed PPV for DME, we always combined cataract surgery, so there is a possibility 
that the cataract removal took part in improving BCVA of PPV group. Those facts indicate that we 
should carefully interpret the results and compare the BCVA between STTA and PPV groups. 
In this study, there was no significant progress of cataract after STTA. There is a possibility that both 
the cataract and improvement of CMT are not relevant to BCVA improvement at 3 or 6 months after 
STTA.  
It is said that VEGF is main cause of DME.¹²⁾ Hyperglycemia, inflammation, and  ischemia 
increase VEGF in retinal cells, and the permeability of retina is up regulated.¹¹⁾¹³⁾ Also, 
hyperglycemia causes inflammation which increases vascular permeability .¹⁴⁾  Those facts 
suggest that IVTA⁷⁾¹⁵⁾ and STTA²⁾¹⁶⁾ restrain inflammation and decrease retinal VEGF expression. 
¹⁷⁾-¹⁹⁾ 
Main complications of IVTA are IOP elevation, endophthalmitis, and cataracts. IVTA recorded 
higher level of IOP elevation than STTA.²⁰⁾Among TA treated eyes, endophthalmitis occurred in 7 
(0.12%) of 5,665 eyes treated with IVTA, and 7 (0.026%) of 26,819 eyes treated with PPV.²¹⁾ On the 
contrast, endophthalmitis occurred only 1 (0.008%) of 12,344 eyes after STTA treatment.²¹⁾ Recent 
study reports that the percentage of endophthalmitis after intravitreal injection of anti-VEGF drugs 
was 0.025% ²²⁾, but anti VEGF drugs are usually injected to vitreous repeatedly for DME  ⁴⁾⁵⁾⁶⁾⁹⁾, 
so the risk of endophthalmitis increases after treatment. The RESOLVE and RESTORE studies 
reported that the rate of endophthalmitis was 1.4% at 1 year.⁴⁾  
Hoerauf et al reported complications of PPV for DME. Among 50 patients, 10 patients had 
iatrogenic tears intraoperatively, 42 phakic eyes developed cataracts within 6 months, 1 patient had 
vitreous hemorrhage after surgery and underwent second vitrectomy with silicone oil tamponadea, 3 
eyes had retinal detachment and underwent second vitrectomy.²³⁾ 
Those facts suggest that STTA has a significantly lower risk than intravitreal injection of anti-VEGF 
drugs, IVTA, and PPV for DME treatment. 
Our study has a limitation because it was a retrospective study, the follow up period was short, the 
group was small. Big scale randomized studies are needed to compare the effectiveness of each 
treatment for DME.  
Conclusion  
Both STTA and PPV significantly reduced CMT in patients with DME, and there were no significant 
differences in BCVA and CMT between the two groups. Also, STTA had less complications than 
PPV, so our results suggest that STTA can be an alternative treatment of  PPV for DME.  
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 PPV STTA P-values 
Age, mean ± SD (years) 62.65 ± 1.55 61.92±2.27 P=0.793 
Sex, no. (%)    
Men 12 ( 46 ) 16( 73 ) P=0.404 
Women 14 ( 54 ) 6 (27)  
Type of diabetes,no (%)    
Type Ⅰ 0 ( 0 ) 1 (5) P>0.999 
Type Ⅱ 26 ( 100 ) 21( 95 )  
Hemoglobin A1c, mean ± SD (%) 6.52 ± 0.19 6.7 ± 1.0 P=0.311 
Treatment of diabetes    
Medication 8 ( 31 ) 14(82)     P=0.161 
Insulin 18 ( 69 ) 3 ( 18 ) P<0.0001 
Diabetic nephropathy, no (%) 13 ( 50 ) 10 ( 56 ) P=0.577 
Pseudophakic eyes 5 5 P>0.999 
BCVA, mean ± SD (logMAR) 0.77±0.31 0.57±0.43 P=0.237 
CMT, mean ± SD (μm) 534±157 551±167 P=0.444 
Table.1  Clinical data and features 
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